Evidence map›Paper›PMID 34751556›Full record

ArticleACS applied materials & interfaces2021

Insulin Granule-Loaded MicroPlates for Modulating Blood Glucose Levels in Type-1 Diabetes.

Rosita Primavera, Elena Bellotti, Daniele Di Mascolo, Martina Di Francesco, Jing Wang, Bhavesh D Kevadiya, Angelo De Pascale, Avnesh S Thakor, Paolo Decuzzi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Rosita PrimaveraLaboratory of Nanotechnology for Precision Medicine, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, Genoa 16163, Italy.ORCID https://orcid.org/0000-0002-6039-5679
Elena BellottiLaboratory of Nanotechnology for Precision Medicine, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, Genoa 16163, Italy.ORCID https://orcid.org/0000-0002-4291-6530
Daniele Di MascoloLaboratory of Nanotechnology for Precision Medicine, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, Genoa 16163, Italy.ORCID https://orcid.org/0000-0002-1422-5775
Martina Di FrancescoLaboratory of Nanotechnology for Precision Medicine, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, Genoa 16163, Italy.ORCID https://orcid.org/0000-0001-9609-5734
Jing WangInterventional Regenerative Medicine and Imaging Laboratory, Department of Radiology, Stanford University, Palo Alto, California 94304, United States.
Bhavesh D KevadiyaInterventional Regenerative Medicine and Imaging Laboratory, Department of Radiology, Stanford University, Palo Alto, California 94304, United States.
Angelo De PascaleUnit of Endocrinology, Department of Internal Medicine & Medical Specialist (DIMI), University of Genoa, 16136 Genoa, Italy.
Avnesh S ThakorInterventional Regenerative Medicine and Imaging Laboratory, Department of Radiology, Stanford University, Palo Alto, California 94304, United States.ORCID https://orcid.org/0000-0001-7395-0515
Paolo DecuzziLaboratory of Nanotechnology for Precision Medicine, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, Genoa 16163, Italy.ORCID https://orcid.org/0000-0001-6050-4188
Italian Institute of Technology · ITStanford University · USUniversity of Genoa · IT

Funding

Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
A novel approach for treating diabetes using pulsed focused ultrasound and intra-arterial delivery of mesenchymal stem cell based therapies directly into the pancreasR01DK119293 · NIDDK · STANFORD UNIVERSITY · PI THAKOR, AVNESH SINH · 2019 to 2023
$2.3M
NIDDK NIH HHS P30 DK116074NIDDK NIH HHS R01 DK119293
6 · The paper itself

Abstract

Type-1 diabetes (T1DM) is a chronic metabolic disorder resulting from the autoimmune destruction of β cells. The current standard of care requires multiple, daily injections of insulin and accurate monitoring of blood glucose levels (BGLs); in some cases, this results in diminished patient compliance and increased risk of hypoglycemia. Herein, we engineered hierarchically structured particles comprising a poly(lactic-

Indexed as

AnimalsBiocompatible MaterialsBlood GlucoseDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Dose-Response Relationship, DrugHypoglycemiaHypoglycemic AgentsInsulinMaleMiceMice, Inbred C57BLParticle SizePolyglycolic AcidStreptozocinBiocompatible MaterialsBlood GlucoseHypoglycemic AgentsInsulinPolyglycolic AcidStreptozocindiabetesdrug deliveryinsulin granulesmicrofabricationmicroparticles

Identifiers

PMID34751556
PMCPMC8603355
OpenAlexW3212525640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.